2002
DOI: 10.1074/jbc.m201327200
|View full text |Cite
|
Sign up to set email alerts
|

Identification of the Regulatory Elements of the Human von Willebrand Factor for Binding to Platelet GPIb

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
6
0

Year Published

2007
2007
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 29 publications
(6 citation statements)
references
References 32 publications
0
6
0
Order By: Relevance
“…One possible explanation is that the amino acid sequence 1238 -1247 from the C terminal end of the D3 domain, which is included in our A1A2A3 construct, forms part of the molecular mechanism that masks the binding site for GPIb␣. In fact, others have proposed that segment as a regulatory element of VWF-GPIb␣ binding (37,38).…”
mentioning
confidence: 99%
“…One possible explanation is that the amino acid sequence 1238 -1247 from the C terminal end of the D3 domain, which is included in our A1A2A3 construct, forms part of the molecular mechanism that masks the binding site for GPIb␣. In fact, others have proposed that segment as a regulatory element of VWF-GPIb␣ binding (37,38).…”
mentioning
confidence: 99%
“…The recent findings of Borthaker et al showed that sulfatide inhibits the binding of beads covalently coupled to the fragment of GPIbα to the VWF-A1 domain [13]. The binding of VWF to GPIb requires conformational change of VWF, induced by shear stress under irregular blood flow [24, 31]. Therefore, it is likely that VWF–sulfatide binding competes with VWF–GPIb binding, and that sulfatides possess antithrombotic properties under some pathological conditions, such as sites of arteriosclerosis or vascular injury where the VWF–GPIb interaction initiates thrombus formation [32].…”
Section: Discussionmentioning
confidence: 99%
“…The preparation of recombinant VWF (rVWF) was described previously [24]. Briefly, human 293T cells, growing in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco-BRL), were transfected by the lipofection method using TransFast transfection kit (Promega, Madison, MI, USA) according to the manufacture’s instructions.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The A1 domain of VWF contains a single intramolecular disulfide bond between C1272 and C1458 that may optimize its structure for platelet binding [8], [9]. The residues N-terminal to C1272 have been proposed to allosterically hinder binding between the A1 domain and GPIb [10], [11], [12]. The contribution of other VWF regions to GPIb binding has been less characterized.…”
Section: Introductionmentioning
confidence: 99%